查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1907873

软组织生物製剂市场：市场规模、占有率、监管、报销、干预措施及2036年预测（按细分市场划分）

Soft Tissue Biologics Market Size by Segments, Share, Regulatory, Reimbursement, Interventions and Forecast to 2036
出版日期: | 出版商: GlobalData | 英文 | 订单完成后即时交付

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

本软组织生物製剂市场（规模、占有率、监管、报销和干预措施）及2036年预测旨在展现骨科器械治疗领域的定量和定性市场趋势。

软组织生物製剂用于外科手术，以取代、加强或修復人体撕裂或受损的肌腱和韧带。软组织生物製剂市场主要集中在修復前十字韧带 (ACL)、后十字韧带 (PCL)、肩袖和跟腱。

骨科软组织生物製剂广泛用于治疗人体撕裂或受损的肌腱和韧带。它们源自天然物质，可用于再生和修復肌肉骨骼组织。

微创手术和关节镜检查有助于早期介入和治疗各种疾病，而再生医学则促进正常组织的生长、扩张和维持。

针对39个目标国家/地区，我们提供了颜色编码、资料来源完整的市场模型，其中包含基于流行病学的适应症和干预量。互动式Excel报表包含价值、数量、产品使用情况、平均售价、市场规模和公司占有率分析（如有）。此外，分析师的评论和定性见解为定量数据提供了背景资讯。

市场模型亮点包括：

目前可用的软组织生物製剂器材及不断变化的竞争格局

  • 对关键产业趋势的深入分析
  • 按细分市场划分的软组织生物製剂器材市场年度总收入及2015年至2036年的市场预测。
  • 按细分市场划分的手术总量、销售量、平均售价和市场规模的详细数据。

全球、区域和国家层面的市场洞察 -

  • 除了定性的市场特定资讯外，我们还提供按区域划分的全球趋势细分分析。此外，GlobalData 分析师还提供针对特定国家市场的独特见解。
  • 软组织生物製剂器材市场的 SWOT 分析。
  • 软组织生物製剂器材市场的竞争格局与趋势。

全面、整体的视角，包括医疗保健系统概览，有助于加深对市场的理解。此外，市场准入部分透过报销政策和监管环境方面的讯息，能够更深入地了解市场动态。

  • 各国医疗保健系统概览。
  • 各国报销政策。
  • 各国医疗科技监管环境。

我们强大的研究方法和资料来源，能够提供全面且准确的市场概览。主要需求方和供应方资讯（包括产业领导企业）已整合到联合分析模型中。此外，我们也利用真实世界的资料来源来了解市场趋势，包括政府手术资料库、医院采购资料库和专有线上资料库。

涵盖的公司：LifeNet Health Inc.、Xtant Medical Holdings Inc.、ConMed Corp.、AlloSource、Arthrex Inc.、Smith & Nephew Plc、Stryker Corp.、Zimmer Biomet Holdings Inc. 等。

涵盖的国家：美国、英国、德国、法国、义大利、西班牙、巴西、中国、印度、俄罗斯、日本、澳洲、加拿大、墨西哥、韩国、丹麦、爱尔兰、荷兰、纽西兰、南非、瑞典、瑞士、奥地利、比利时、芬兰、以色列、挪威、波兰、葡萄牙、台湾、捷克共和国、希腊、匈牙利、土耳其、埃及、沙乌地阿拉伯、阿拉伯联合大公国、阿根廷和智利。

范围

此市场模型提供您在其他任何地方都找不到的关键且专业的见解。该模型揭示了特定市场中的定性和定量趋势。以下人士的必读之作：

  • 需要深入了解软组织生物製剂市场，以便制定策略规划和投资决策的首席行销长 (CMO)。
  • 需要了解供应链关键组成部分，以便进行供应商选择和管理决策的采购主管。
  • 需要深入了解市场，以便识别和评估潜在投资目标的私募股权投资者。

购买理由

模型可帮助您：

  • 审查在研产品，以识别关键公司，并制定和设计引进和转让许可策略。
  • 透过了解塑造和驱动软组织生物製剂市场的趋势，制定您的业务策略。
  • 透过了解关键趋势、创新产品和技术、市场细分以及未来将影响软组织生物製剂市场的公司，实现收入成长。
  • 透过了解竞争格局并分析市场领导者的市场占有率，制定有效的销售和行销策略。
  • 识别具有潜在强大产品组合的新兴公司，并制定有效的应对策略以获得竞争优势。
  • 追踪2015年至2036年全球及各国软组织生物製剂市场的器材销售情形。
  • 识别最具整合、投资和策略联盟机会的市场类别和细分市场，并据此调整您的销售和行销工作。
简介目录
Product Code: GDME523MM

Soft Tissue Biologics Market Size by Segments, Share, Regulatory, Reimbursement, Interventions and Forecast to 2036 is built to visualize quantitative and qualitative market trends within Orthopedic Devices therapeutic area.

Soft Tissue Biologics are used in surgical Interventions to replace, reinforce, or repair tendons or ligaments that have been torn or damaged in the human body. Soft Tissue Biologics market focuses on the repair of the anterior cruciate ligament (ACL), posterior cruciate ligament (PCL), rotator cuff, and Achilles's tendon.

Orthopedic soft tissue biologics are widely used in Interventions where tendon or ligament is torn or damaged in the human body. They are made from substances that are naturally found in the body and can be used in regeneration and repair of the musculoskeletal tissues.

Minimally invasive surgery and arthroscopy has helped in early intervention and treatment of multiple medical conditions and regenerative medicine has facilitated the in-growth, expansion and preservation of the normal tissue.

Each of the covered 39 countries color-coded and fully-sourced market models are equipped with epidemiology based indications with intervention volumes. The interactive excel deliverable covers value, volumes, product usage, average selling prices, market size and company share/rank analysis (wherever available). Moreover, analyst comments with qualitative insights offer context for quantitative data.

Key Inclusions of the market model are -

Currently marketed Soft Tissue Biologics Devices and evolving competitive landscape -

  • Insightful review of the key industry trends.
  • Annualized total Soft Tissue Biologics Devices market revenue by segment and market outlooks from 2015-2036.
  • Granular data on total Interventions, units, average selling prices and market values by segment.

Global, Regional and Country level market specific insights -

  • Qualitative market specific information is available with global trends further broken down into regional trends. In addition GlobalData analysts provide unique country specific insights on the market.
  • SWOT analysis for Soft Tissue Biologics Devices market.
  • Competitive dynamics insights and trends provided for Soft Tissue Biologics Devices market.

Drive the understanding of the market by getting the veritable big picture including an overview of the healthcare system. In addition the Market Access segment allows you to delve deeper into market dynamics with information on reimbursement policies and the regulatory landscape.

  • Country specific overview of the healthcare system.
  • Country specific reimbursement policies.
  • Country specific medtech regulatory landscape.

Robust methodologies and sources enable the model to provide extensive and accurate overview of the market. Demand and supply-side primary sources are integrated within the syndicated models, including Key Opinion Leaders. In addition, real world data sources are leveraged to determine market trends; these include government procedure databases, hospital purchasing databases, and proprietary online databases.

Companies covered: LifeNet Health Inc, Xtant Medical Holdings Inc, ConMed Corp, AlloSource, Arthrex Inc, Smith & Nephew Plc, Stryker Corp, Zimmer Biomet Holdings Inc, and Others.

Countries covered: United States, United Kingdom, Germany, France, Italy, Spain, Brazil, China, India, Russia, Japan, Australia, Canada, Mexico, South Korea, Denmark, Ireland, Netherlands, New Zealand, South Africa, Sweden, Switzerland, Austria, Belgium, Finland, Israel, Norway, Poland, Portugal, Taiwan, Czech Republic, Greece, Hungary, Turkey, Egypt, Saudi Arabia, United Arab Emirates, Argentina and Chile.

Scope

This Market Model gives important, expert insight you won't find in any other source. The model illustrates qualitative and quantitative trends within the specified market. This model is required reading for:

  • CMO executives who must have deep understanding of the Soft Tissue Biologics marketplace to make strategic planning and investment decisions.
  • Sourcing and procurement executives who must understand crucial components of the supply base in order to make decisions about supplier selection and management.
  • Private equity investors that need a deeper understanding of the market to identify and value potential investment targets.

Reasons to Buy

The model will enable you to:

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products, by identifying key companies.
  • Develop business strategies by understanding the trends shaping and driving Soft Tissue Biologics.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the Soft Tissue Biologics market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the company share of market leaders.
  • Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
  • Track device sales in the global and country-specific Soft Tissue Biologics market from 2015-2036.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.